1.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and under
Sponsor: Other
Protocol IDs: AML99<=65 años, NCT00390715
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: LAL-RI/96, NCT00494897
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDL-3-251, MSKCC-93131, NCI-V94-0469
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 18
Sponsor:
Protocol IDs: SJCRH-ALL-TT-8
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 60
Sponsor:
Protocol IDs: NCI-D81-018-590, DFCI-80035
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NCI-D82-051-605
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: CCG-192P
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 1 to 20
Sponsor: NCI
Protocol IDs: POG-8698
|
|
9.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: SJCRH-AML-87, NCI-T86-0203D, T86-0203
|
|
10.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: NCI
Protocol IDs: POG-8862
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 20
Sponsor:
Protocol IDs: ARG-GATLA-1LLAREC90, NCI-F92-0006, NCT00002499
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 17
Sponsor:
Protocol IDs: GER-GPOH-AML-BFM-93, EU-93008
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor:
Protocol IDs: EORTC-06931, NCT00002549
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 21 at diagnosis
Sponsor: NCI
Protocol IDs: POG-9406, POG-ALINC-16/HR
|
|
15.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 56 and over
Sponsor: NCI
Protocol IDs: SWOG-9333
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 21
Sponsor: NCI
Protocol IDs: POG-9421
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to physiologic 59
Sponsor: Other
Protocol IDs: MRC-LEUK-AML12, EU-95001, NCT00002658
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor: Other
Protocol IDs: EORTC-06951, FRE-LALA-94, NCT00002700
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 9
Sponsor: NCI
Protocol IDs: CCG-1952, NCT00002744
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 1 and under 15
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-XI, EU-95036
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: MRC-LEUK-AML-R, EU-95037
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MSKCC-96015A1, NCI-V96-0881, NCT00002766
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: COG-2961, CCG-2961, NCT00002798
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: CCG-1961, NCT00002812
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: RPCI-DS-96-28, SEQUUS-30-38, NCI-G97-1241, NCT00002985
|
